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Abstract
Background: Although the efficacy of standard fish oil has been the subject of research in arthritis, the effect of krill oil 
in this disease has yet to be investigated. The objective of the present study was to evaluate a standardised preparation 
of krill oil and fish oil in an animal model for arthritis.
Methods: Collagen-induced arthritis susceptible DBA/1 mice were provided ad libitum access to a control diet or diets 
supplemented with either krill oil or fish oil throughout the study. There were 14 mice in each of the 3 treatment 
groups. The level of EPA + DHA was 0.44 g/100 g in the krill oil diet and 0.47 g/100 g in the fish oil diet. Severity of 
arthritis was determined using a clinical scoring system. Arthritis joints were analysed by histopathology and graded. 
Serum samples were obtained at the end of the study and the levels of IL-1α, IL-1β, IL-7, IL-10, IL-12p70, IL-13, IL-15, IL-17 
and TGF-β were determined by a Luminex™ assay system.
Results: Consumption of krill oil and supplemented diet significantly reduced the arthritis scores and hind paw 
swelling when compared to a control diet not supplemented with EPA and DHA. However, the arthritis score during 
the late phase of the study was only significantly reduced after krill oil administration. Furthermore, mice fed the krill oil 
diet demonstrated lower infiltration of inflammatory cells into the joint and synovial layer hyperplasia, when compared 
to control. Inclusion of fish oil and krill oil in the diets led to a significant reduction in hyperplasia and total histology 
score. Krill oil did not modulate the levels of serum cytokines whereas consumption of fish oil increased the levels of IL-
1α and IL-13.
Conclusions: The study suggests that krill oil may be a useful intervention strategy against the clinical and 
histopathological signs of inflammatory arthritis.
Background
Arthritis and musculoskeletal disorders are among the
most prevalent chronic conditions affecting the US popu-
lation [1]. Osteoarthritis, also known as osteoarthrosis or
degenerative joint disease, is the most common type of
arthritis, characterised primarily by cartilage loss and
synovitis as a result of the aging process and affects
approximately 12.1% of the US population aged 25 years
or older [1,2]. Similarly, rheumatoid arthritis (RA) is a
major cause of morbidity in the Western world [3]. The
disease occurs in 0.5-1% of the worldwide adult popula-
tion and in 1% of the US adult population [4,5]. In con-
trast to osteoarthritis, the pathologic feature of RA is an
autoimmune disorder characterized by the presence of
Rheumatoid factor and anti-citrullinated protein anti-
bodies.
The most commonly used non-clinical model of arthri-
tis is Collagen-Induced Arthritis (CIA) and was first
reported by Trentham and colleagues where they induced
the disease in rats following a single intradermal injection
of type II collagen emulsified in Complete Freund's adju-
vant (CFA) [6]. A few years later the same pathology was
demonstrated in mice [7]. Immunisation with emulsified
type II collagen results in a severe polyarthritis reaction
which commences 3-4 weeks after the primary immuni-
zation. A secondary challenge with type II collagen alone
is often required 21 days following the first challenge to
ensure optimal arthritis incidence. Similar to RA, the
pathogenesis of CIA is a multistep process driven by
major histocompatibility complex restricted T cells that
mediate destruction of the joint characterized by fibrin
deposition, synovial inflammation, periosteal bone for-
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Page 2 of 11mation, pannus formation and ankylosis of one or more
articular joints [6,8].
An autoimmune Th1 environment is crucial in the
induction and pathogenesis of both clinical RA and in the
CIA experimental model in rodents. IFN-γ is produced
very early in lymph nodes following primary immuniza-
tion with collagen/CFA and declines by the end of the
acute phase [9]. TNF-α released by synovial macrophages
is critical in the pathogenesis of the disease since TNF-α
is found in most biopsies and is a target for many of the
biological therapeutic agents currently on the market
where it reduces clinical responses in 70% of recipient
patients with established RA by attenuating acute phase
proteins and IL-6 [4]. Anti-TNF agents can halt the pro-
gression of bone and cartilage degradation by suppressing
bone-resorbing osteoclasts in joint lesions [10]. However,
there are a significant proportion of patients who do not
respond to TNF blockade through administration of Inf-
liximab or Etanercept [11]. Furthermore, patients can be
rendered susceptible to opportunistic infections such as
tuberculosis [4]. Hence, it is vital to identify alternative
treatments which could address this unmet clinical need
with fewer potential side effects.
The two main categories of polyunsaturated fatty acids
(PUFAs) are (n-3) and (n-6). The effect of fish oils on RA
has been reviewed in several papers [12-14]. Overall,
dietary (n-3) fat has modest therapeutic benefits in sev-
eral inflammatory diseases such as cardiovascular disease
[15], atopic dermatitis [16] and arthritis [17-24]. Two dif-
ferent meta-analyses have been published: one including
9 trials published between 1985 and 1992 [25], and
another one describing 10 trials published between 1985
and 2002 [26]. In summary, most of the trials where fish
oil was administered to patients with RA demonstrate
disease modifying effects, and the reviews and meta-
analyses concludes that there is strong evidence that (n-3)
PUFAs have some clinical benefits in RA. One of the
mechanisms by which inflammation is reduced is pro-
posed to be related to the incorporation of eicosapen-
taenoic acid (EPA) into phospholipid membrane of
macrophages, which results in decreased production of
arachidonate products [27].
Krill oil is extracted from Antarctic Krill (Euphausia
Superba), which is a zooplankton crustacean that is rich
in phospholipids [28]. In common to fish oils, krill oil
contains a high proportion of (n-3) fatty acids. However,
krill oil contains a major part of the (n-3) fatty acids in the
form of phospholipids, which makes this oil different
from fish oils which contain (n-3) fatty acids in the form
of either triacylglycerol or fatty acid ethyl esters (such as
Omacor/Lovaza). Phospholipids are the primary struc-
tures of human cell membranes and the "gatekeepers" of
cells through the regulation of healthy cell membranes.
The association between phospholipids and long-chain
(n-3) fatty acids might facilitate the passage of fatty acid
molecules through the intestinal wall, increasing their
bioavailability and ultimately improving the (n-3):(n-6)
ratio. Interestingly, a recent study demonstrated that oral
phosphatidylcholine pretreatment had beneficial effects
on the morphological, functional and microcirculatory
characteristics of chronic arthritis [29]. In addition to
phospholipids, krill oil also contains the antioxidant
astaxanthin, mainly in the ester form [28].
In this study, we wanted to compare and investigate
whether the administration of krill oil or fish oil, with
comparable levels of EPA and docosahexaenoic acid
(DHA), could suppress the development of CIA in the
genetically susceptible DBA/1 mouse strain. Effects upon
the macroscopic changes to the joint, disease incidence,
joint destruction and the systemic levels of important
inflammatory mediators responsible for pathology were
investigated.
Methods
Rats and palatability study
Two groups of 2 month old male Wistar rats (n = 5), ini-
tial weight 245 to 254 g, were kept in metabolic cages and
fed either a control diet supplemented with rapeseed oil
(2.5 g/100 g of diet) or a test diet supplemented with an
equal amount of krill oil (Superba™ Krill Oil, Aker BioMa-
rine ASA, Oslo, Norway). Each day the rat weight as well
as the amount of food consumed was measured for indi-
vidual rats.
Mice
3.5 week old male DBA/1 mice were obtained from Har-
lan, Israel, and housed within the rodent facility at MD
Biosciences, Israel. 42 mice were allowed to acclimatise
for two weeks prior to study commencement, during this
time they had free access to a standard rodent chow
(Teklad) and to drinking water. At study commencement
(25 days prior to arthritis induction) the mice were pro-
vided ad libitum access to control diet or diets supple-
mented with either fish oil (GC Rieber Oils, AS,
Kristiansand, Norway), or krill oil (Superba™ Krill oil,
Aker BioMarine ASA, Oslo, Norway). There were 14
mice in each of the 3 treatment groups at the start of the
study. 1 mouse in the krill oil group did not recover from
the anaesthesia after induction of arthritis as described
below (Day 27). Further, a total of 15 mice were culled
due to arthritis severity during the study. Among these, 8
belonged to the control group, 2 belonged to the krill oil
group and 5 belonged to the fish oil group. These 15 mice
were culled at Day 62 or 64.
Diets
The diets were based on the AIN-93G formulation [30],
with substitution of soybean oil with a blend of oils (rape-
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substitution allowed the 3 diets to be similar for total fatty
acids, and for oleic, linoleic and alpha linolenic acids. Fish
oil and krill oil diets were further balanced for EPA and
DHA content. The 3 diets were prepared by Altromin
GmbH & Co. KG (Lage, Germany) and stored in vacuum
bags to reduce (n-3) PUFA oxidation. The fatty acid com-
position of the diets is presented in Table 1. The contents
of EPA + DHA were comparable between the two treat-
ments (0.44 g/100 g of krill oil diet and 0.47 g/100 g of fish
oil diet). This level of EPA + DHA in the diets is equiva-
lent to 0.8 en%, which was chosen to provide a level of (n-
3) PUFA intake achievable in humans, and corresponds
to 1.8 g d-1 on a 8400 kJ diet in humans. Fresh food was
supplied daily throughout the study. Mice continued to
have free access to drinking water. All animal experiment
procedures were performed according to the guidelines
and protocols approved by the Committee for Ethical
Conduct in the Care and Use of Laboratory Animals in
Israel.
Body weight following arthritis induction
Body weights were determined on day 0 and twice weekly
thereafter throughout the study.
Induction of arthritis
Following 25 days of feeding with the supplemented diets,
arthritis was induced in all mice by the intradermal injec-
tion of bovine type II collagen (200 μg/mouse) (MD Bio-
sciences, Minneapolis) emulsified in complete Freund's
adjuvant (MD Biosciences) at the base of the tail under
anaesthesia. Twenty-two days later (study day 47) mice
were boosted with an intraperitoneal injection of bovine
type II collagen (200 μg/mouse).
Clinical arthritis assessment
Following the intraperitoneal collagen boost on day 47
clinical signs of arthritis were assessed in all paws three
times weekly according to a 0-4 scale of ascending sever-
ity. Briefly, grade 0 indicated no swelling or erythema;
grade 1, mild, but definite redness and swelling of the
ankle/wrist or apparent redness and swelling limited to
individual digits, no matter the number of affected digits;
grade 2, moderate to severe redness and swelling of the
ankle/wrist; grade 3, redness and swelling of the entire
paw including digits; grade 4 maximally inflamed limb
with involvement of multiple joints. Thus the maximum
score for four fully inflamed paws would be 16. Paw thick-
ness as a measure of swelling was determined in mm
three times weekly using dial calipers (Kroeplin, Munich,
Germany).
Histopathological assessment of arthritis
At termination, the mouse paws were cut using scissors
above the knee joint and fixed in 10% formalin for at least
one week. The tissues were then decalcified, trimmed
and the knee joints embedded in paraffin. A 6 μm section
was cut and stained with haematoxylin and eosin (H&E).
The stained knee sections were examined and scored for
the parameters, inflammatory infiltrate, synovial hyper-
plasia and the erosion of cartilage and bone as described
in Table 2. Where an animal was found to be intermediate
between a score (e.g. between a 1 and 2) then an interme-
diate score was assigned (e.g. 1.5). This scoring was
blinded, with the scorer unaware of the identity of the
Table 1: Dietary fatty acid composition
Fatty acid Control Fish Oil Krill Oil
g/100 g diet
18:3 (n-3) 0.26 0.26 0.29
18:4 (n-3) - 0.05 0.08
20:5 (n-3 - 0.29 0.30
22:6 (n-3) - 0.18 0.14
Σ n-3 0.26 0.78 0.81
18:2 (n-6) 2.07 2.23 2.22
20:4 (n-6) - 0.01 0.01
Σ n-6 2.07 2.24 2.23
(n-6)/(n-3) 7.85 2.86 2.76
18:1 (n-9) 2.34 2.72 2.25
Σ unsaturated 4.68 5.74 5.29
12:0 1.09 0.04 0.02
14:0 0.39 0.20 0.38
16:0 0.58 0.78 1.09
18:0 0.22 0.21 0.19
20:0 0.03 0.04 0.03
Σ saturated 2.32 1.26 1.71
Unsaturated/saturated 2.02 4.54 3.10
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blinded for data analysis.
Assessment of systemic cytokine levels
Upon termination of the study blood samples were taken
and serum prepared from all surviving mice. Blood was
obtained directly by cardiac puncture, and the collected
volume was the maximum amount obtainable. Serum
samples were stored at -20°C. A blood sample was also
taken from any animals culled due to severity of arthritis.
The levels of IL-1α, IL-1β, IL-7, IL-10, IL-12p70, IL-13,
IL-15, IL-17 and TGF-β were then assessed using
Luminex™ multiplex reagents according to the manufac-
turer's instructions (Millipore, St Charles, MO). For mea-
surement of interleukins we used a Mouse Cytokine/
Chemokine Panel, 8-plex (Millipore, cat. no. MPXM-
CYTO-70K-08). Due to reagent incompatibilities, TGF-β
was assayed separately from the other cytokines. For
measurement of TGF-β, TGF-beta1, 1-plex (Millipore,
cat. no. TGFB-64K-01) was used. Data were collected
using a Luminex 100 (Luminex Corporation, Austin, TX).
The lowest limit of detection was 5.1 pg/ml for IL-1α, 2
pg/ml for IL-1β, 0.9 pg/ml for IL-7, 3.3 pg/ml for IL-10,
4.1 pg/ml for IL-12p70, 6.3 pg/ml for IL-13, 6.5 pg/ml for
IL-15, 0.5 pg/ml for IL-17 and 10 pg/ml for TGF-β. Stan-
dard curves were generated using a 5-parameter logistic
curve-fitting equation weighted by 1/y (StarStation V 2.0;
Applied Cytometry Systems, Sacramento, CA). Each
sample reading was interpolated from the appropriate
standard curve.
Fatty acid analysis
The fatty acid composition [31] and the method of fatty
acid analysis [32] of the diets have been previously
described.
Statistical analysis
Where appropriate data are expressed as the group mean
± standard error of the mean (SEM). The statistical sig-
nificances of any treatments was determined by ANOVA
with Tukey post hoc testing (arthritis scores, paw thick-
ness, body weight and histology scores) or Mann Whit-
ney U test (palatability data and cytokine levels) using the
JMP 8.0 (SAS Institute Inc., Cary, NC). A p-value of less
than 0.05 was taken to be significant. Correlations
between the arthritis score and body weight at the time of
primary immunization with Type II Collagen was carried
out using the Spearman Rank Correlation Analysis in
Winstat™ add-in for Excel™. A p-value of less than 0.05
was deemed to be significant.
Results
Dietary supplementation with krill oil reduces clinical 
arthritis signs in mice
An initial palatability study was carried out in rats to
ensure that the addition of krill oil to the feed did not
affect the consumption of food. Rats fed on either rape-
seed oil or krill oil supplemented diet gained weight in a
similar fashion over the 16 days and consumed similar
amount of chow (data not shown). Starting weights were
Table 2: Histopathological scoring of joint sections
Parameter Score
Infiltrate
No infiltrate detected. 0
Modest leukocyte infiltrate in synovial tissue, no fluid 
leukocytes.
1
Moderate leukocyte infiltrate in synovial tissue and in fluid 
phase with loss of synovial architecture.
2
Gross leukocyte infiltrate in synovial membrane and fluid 
space with significant loss of synovial and articular 
architecture.
3
Hyperplasia
No abnormalities detected. 0
Synovial lining layer 2-4 cells thick. 1
Synovial lining layer >5 cells thick associated with moderate 
expansion of the sub lining layer zone.
2
Synovial lining layer >5 cells thick associated with significant 
expansion of the sub lining layer zone and potentially with 
loss of synovial architecture.
3
Erosion of cartilage/bone
No abnormalities detected. 0
Fibrillation of cartilage and/or mild erosive infiltration of 
periosteal and subchondral bone. Nuclei intact within 
lacunae.
1
Moderate fibrillation and loss of cartilage and/or moderate 
erosive infiltration of periosteal and subchondral bone. 
Nuclei may show apoptosis within lacunae.
2
Significant loss of cartilage and/or erosive infiltration of 
periosteal and subchondral bone. Nuclei show apoptosis 
within lacunae across a wide area of cartilage/bone.
3
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Page 5 of 11247.6 ± 0.87 g for rapeseed oil supplemented controls and
251.2 ± 1.53 g for rats fed the krill oil supplemented diet.
Thus, it was concluded that dietary supplementation with
krill oil does not affect palatability of the feed.
As illustrated in Figure 1, arthritis was induced in male
DBA/1 mice that had been fed on either control, fish oil
supplemented or krill oil supplemented diets for 25 days,
by an intradermal injection of bovine type II collagen in
CFA followed 22 days later by an intraperitoneal injection
of collagen (collagen boost, study day 47). Feeding with
the supplemented and control diets was continued
throughout the study until day 68.
Clinical arthritis was first noted in the mice fed the
control diet on day 45 (prior to the collagen boost, Table
3), and the incidence of disease steadily increased reach-
ing 100% on day 60. Externally, the animals' joints
appeared reddened and swollen, with the mean clinical
arthritis score reaching 11.29 ± 0.9 (out of a maximum of
16, Figure 1A) on day 68. 8 animals within this group
were culled due to welfare as disease was deemed to be
too severe, leaving 6 survivors at the end of the study.
In the animals fed diets supplemented with either fish
oil or krill oil, disease incidence increased more slowly
and was not observed at all in the mice fed krill oil sup-
plemented diet until day 54 when it was only 15.4%, com-
pared to the mice fed the control diet where the incidence
was 42.9%. This is consistent with the clinical arthritis
scoring, which was found to be significantly lower in mice
fed the diet supplemented with krill oil compared to that
observed in mice fed control diet on study days 54-68.
Arthritis score in fish oil supplemented mice were signifi-
cantly lower than control at day 54, 56 and 58. Further-
more, at the end of the study there were a total of 11
survivors in the group fed with krill oil in comparison to 9
survivors in the group fed with fish oil.
Dietary supplementation with krill oil reduces hind paw 
thickness in mice
The extent of hind paw swelling was assessed using a dial
caliper (Figure 1B). Hind paw swelling was significantly
lower in krill oil supplemented mice at day 54, 60, 62 and
66, compared to control mice. Paw thickness in mice
administered fish oil was different from control animals
at day 49 and 54. In all groups, the main increase in hind
paw swelling occurred after day 58.
Dietary supplementation with krill oil reduces 
histopathology associated with arthritis in mice
At termination the rear paws were removed and prepared
for histopathological analysis. The knee joints were
examined microscopically and scored for signs of inflam-
matory cell infiltrate (Figure 2A), hyperplasia of the syn-
ovial membrane (Figure 2B), erosion of the bone and
cartilage (Figure 2C) and total histology score (Figure
2D). In the knees of arthritic mice fed the control diet,
inflammatory infiltrate, synovial hyperplasia and bone/
cartilage erosion were observed with mean scores of 2.57
± 0.22, 2.39 ± 0.19 and 1.21 ± 0.21, respectively. Mice fed
the supplemented diets showed reduced histopathologi-
cal scores for all the variables measured, in particular in
mice fed the krill oil supplemented diet, which had signif-
icantly lower joint infiltrates (1 ± 0.39) and hyperplasia
scores (0.70 ± 0.32). Fish oil supplementation led to a sig-
nificantly altered synovial hyperplasia score (1.36 ± 0.3)
only. Total scores were significantly reduced in mice fed
both krill oil (2.29 ± 0.94) and fish oil supplemented diets
(3.64 ± 0.77) compared to mice fed the control diet (6.18
± 0.54).
Figure 1 Krill oil and fish oil reduce clinical arthritis signs in mice. 
A) Clinical arthritis scores in DBA/1 mice following induction of colla-
gen induced arthritis with collagen boost on study day 47. B) Hind paw 
thickness (mm) measurements in DBA/1 mice following induction of 
collagen induced arthritis on study day 47. Data represents mean val-
ues ± SEM (n = 13-14). For mice that were culled due to arthritis sever-
ity, the values for the last measurement of clinical arthritis scores and 
hind paw thickness were used for calculations throughout the rest of 
the study. * Significantly different from control group (P < 0.05).
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gain
Body weight was measured twice weekly throughout the
study and weight increased in all treatment groups until
day 54 (Figure 3). After day 54, the weight decreased in all
three treatment groups. This drop in body weight coin-
cided with the development of more severe arthritis (Fig-
ure 1A). In mice fed krill oil supplemented diet, weight
increase started 2 days earlier than in the other treatment
groups although the rate of weight increase appeared to
be similar in all groups. This resulted in a significantly
higher mean body weight in krill oil fed mice from day 2
until study termination on day 68.
Dietary supplementation with krill oil does not affect 
serum cytokines in arthritic mice
The levels of systemic IL-1α, IL-1β, IL-7, IL-10, IL-12p70,
IL-13, IL-15, IL-17 and TGF-β were analysed in the
serum of mice upon termination. Low baseline levels of
IL-7, IL-10, IL-12p70, TGF-β and IL-17 were found in all
mice (data not shown). Higher levels of IL-1α, IL-1β and
IL-13 were found in the serum from CIA mice (Figure 4).
Levels of IL-1α in mice fed fish oil were significantly
higher than in mice fed control or krill oil diet (Figure
4A). The IL-1β level tended to increase after fish oil
administration, but was not significant (Figure 4B) (P =
0.086). The serum level of IL-13 was significantly elevated
after treatment with fish oil, but not krill oil (Figure 4C).
Between the treatment groups, there were no significant
differences between the other cytokines investigated
(data not shown).
Discussion
It has been known for many years that fish oil is able to
benefit the joint pain associated with RA [12-14]. In this
study, a CIA model was used to compare the effects of
krill oil and fish oil on the development of RA. Indeed,
the results of this study clearly demonstrate that supple-
mentation of a diet with krill oil is able to significantly
inhibit the development of arthritis in the CIA model.
This is the first report of krill oil in this or any other
experimental animal model of arthritis. At some time
points, fish oil also demonstrated a reduction in clinical
arthritis score.
The initial palatability study indicated that the krill oil
supplemented diet would not affect body weight of ani-
mals. During the CIA study, mice fed the krill oil diet had
significantly higher body weights from day 3 of the study.
In order to explain why krill oil fed mice did not develop
arthritis to the same extent as control mice, we per-
formed statistical analysis to explore whether mice with a
higher body weight at the time of the collagen boost cor-
related with a lower arthritis score at the end of the study.
The Spearman Rank Correlation Analysis revealed that
there was no significant correlation between individual
Table 3: Clinical arthritis scores and arthritis incidence (%) in DBA/1 mice following induction of collagen-induced arthritis 
with collagen boost on study day 47
Day
45 47 50 52 54 56 58 60 62 64 68
Control Mean Clinical Arthritis Score 0.21 0.21 0.29 0.43 1.36 1.79 5.07 8.71 9.07 10.93 11.29
SEM 0.15 0.15 0.22 0.25 0.48 0.58 0.71 0.86 0.69 0.92 0.90
% Arthritis Incidence 14.3 14.3 14.3 21.4 42.9 57.1 92.9 100 100 100 100
n = 14 14 14 14 14 14 14 14 14 14 14
Number of survivors 14 14 14 14 14 14 14 14 14 6 6
Fish Oil Mean Clinical Arthritis Score 0 0.07 0.14 0.14 0 0 1.50 6.21 7.14 7.57 8.36
SEM 0 0.07 0.10 0.10 0 0 0.51 0.76 0.92 1.08 1.01
% Arthritis Incidence 0 7.1 14.3 14.3 0 0 57.1 100 100 100 100
n = 14 14 14 14 14 14 14 14 14 14 14
Number of survivors 14 14 14 14 14 14 14 14 11 9 9
Krill Oil Mean Clinical Arthritis Score 0 0 0 0 0.23 0.31 1.15 4.69 4.54 5.23 5.92
SEM 0 0 0 0 0.17 0.24 0.39 1.00 1.04 1.15 1.44
% Arthritis Incidence 0 0 0 0 15.4 15.4 46.2 76.9 76.9 84.6 76.9
n = 13 13 13 13 13 13 13 13 13 13 13
Number of survivors 13 13 13 13 13 13 13 13 13 11 11
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krill oil supplemented mice already had significantly
higher body weights but before development of signifi-
cant arthritis) and the final arthritis score for individual
mice. Therefore, it is less likely that the ability of krill oil
to significantly reduce arthritis severity was simply a
result of altered body weight prior to development of
arthritis. The increase in body weight after krill oil sup-
plementation is inconsistent with data from another
study in mice [33]. In this study, however, mice were
administered a high fat diet and the two models are
therefore not directly comparable. In addition, data from
a toxicology study with krill oil in Wistar rats do not show
any significant weight gain after 13 weeks of feeding (data
not published).
We also investigated whether the expression of several
pro-inflammatory cytokines were altered in mice fed the
krill oil or fish oil supplemented feeds. Since pro-inflam-
matory cytokines such as IL-1, TNF-α and IL-17 are
known to drive the joint pathology in RA by activating
inflammatory cells and inducing the release of other
mediators such as MMPs and causing osteolysis [34], we
investigated whether treatment with either fish oil or krill
oil supplemented diets would significantly alter the levels
of a range of pro- and anti-inflammatory cytokines. We
did not find any association between cytokine levels and
severity of the disease. Neither of the supplemented diets
was able to reduce the expression of pro-inflammatory
cytokines. In fact we found that fish oil actually slightly
increased the amounts of IL-1α and IL-13 in the serum of
Figure 2 Krill oil and fish oil reduce histopathology associated with arthritis in mice. Histopathology scores in sections taken from knee joints 
of arthritis induced DBA/1 mice on termination of the study. Sections were scored for cell infiltrations (A), synovial hyperplasia (B), bone/cartilage ero-
sion (C) and total histology score (D). Data represents mean values ± SEM (n = 13-14). * Significantly different from control group (P < 0.05).
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Page 8 of 11mice. It may be that fish oil is able to alter the cytokine
milieu towards a more Th2 profile, and hence we saw a 2-
fold increase in IL-13 levels. However, the majority of
cytokine data found in this study would suggest that sys-
temic cytokines are not good biomarkers for the severity
of the study. Future studies would seek to investigate
cytokine mRNA expression directly within the joint.
Moving into the joint rather than the circulation, it is
known that the pathology seen in the CIA model is simi-
lar to that in human RA [6] with inflammatory cell influx,
synovial hyperplasia, pannus formation and cartilage/
bone erosion.
It has previously been shown that diets rich in fish oil
are able to benefit the pathology detected in osteoarthri-
tis susceptible mouse strains [35]. Mice fed fish oil sup-
plemented diets had reduced synovitis when compared to
corn oil supplemented diets. We have expanded this
information on osteoarthritis to include proof that both
krill oil and fish oil can protect against the joint damage
seen in RA. In this study, supplementation of the diet
with krill oil significantly reduced the magnitude of cell
influx, significantly reduced the thickening of the syn-
ovial membrane and reduced the cartilage erosion seen in
control animals. Krill oil exerted these effects at a level
greater than that seen with the fish oil and was the only
supplemented diet able to reduce inflammatory cell infil-
tration into the joint.
In the present study, krill oil was able to reduce the
severity of arthritis by about 50%. To put these results
with krill oil into context, there have been several investi-
gations with other dietary supplements in the robust CIA
model. In a recent publication it was investigated how the
Figure 3 Effect of krill oil and fish oil on body weight changes in mice. Mean body weights of DBA/1 mice following induction of collagen in-
duced arthritis with collagen boost on study day 47. Data represents mean values of living mice ± SEM. * Significantly different from control group (P 
< 0.05).
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Page 9 of 11severity of CIA was affected in mice given a diet supple-
mented with conjugated linoleic acid (CLA) [36]. CLA
was able to slightly delay the onset of arthritis but did not
result in significant reduction in arthritis scores. Hence
any effect that CLA may have is mild to moderate in com-
parison to that exerted by krill oil. Even with such a mild
effect seen with CLA supplementation, there is still quite
widespread interest in using CLA as a supplement [37]. In
a previous study in a CIA model, the effect of fish oil was
compared with corn oil [38]. The researchers found that
fish oil delayed the onset (34 d compared with 25 d) and
reduced the incidence (69% compared with 93%) and
severity (6.7 compared with 9.8) of CIA. This study was,
however, not directly comparable with our study since
they had different mice strain (B10 mice) and higher level
of fish oil included in the diet (approximately 3 times
higher level of EPA and DHA). However, the study sup-
ports our findings that oils rich in (n-3) have beneficial
effects in experimental models of arthritis.
One factor that differentiates krill oil from fish oil is the
presence of phospholipids in krill oil. More than 40% of
the oil consists of phospholipids, and the majority of
these phospholipids contain (n-3) fatty acids (data to be
published). Unfortunately, little scientific attention has
been paid to the absorption and distribution of dietary
phospholipids, and almost exclusively, all studies on (n-3)
fatty acids in human and experimental animal models
have been performed using such fatty acids in either tria-
cylglycerol form, free fatty acid form, or as fatty acid ethyl
esters. There is some evidence, however, that the absorp-
tion and the distribution of fatty acids from dietary phos-
pholipids can be different than the corresponding fatty
acids from triacylglycerol [39-41]. Fatty acids from
dietary phospholipids have been reported to be taken up
in the brain 2.1-fold more efficiently than fatty acids from
triacylglycerol [42]. It has been reported a difference in
the pharmacokinetic properties between fatty acids origi-
nating from phospholipids versus triacylglycerol [43], and
the absorption, intestinal metabolism and distribution of
(n-3) fatty acids from dietary phospholipids might be dif-
ferent than (n-3) fatty acids from triacylglycerol. Indeed,
in Zucker rats, EPA and DHA from krill oil were more
efficiently incorporated into heart phospholipids, com-
pared to EPA and DHA from fish oil [31]. Moreover, a
higher incorporation of DHA into brain was also
reported after krill oil administration to Zucker rats [44].
Whether this is relevant for the effects observed in the
current study is not known, but one possibility is that (n-
3) fatty acids from krill oil and fish oil have different
effects on inflammation. These mechanisms are only left
to speculations, but can for example be related to a differ-
ent uptake of (n-3) fatty acids in neutrophils and, conse-
quently, an altered lipid composition and function of
neutrophils [45]. The presence of EPA, DHA and arachi-
donic acid in neutrophil phospholipids after krill oil and
fish oil administration should be investigated in future
studies.
Another difference between krill oil and fish oil is the
presence of astaxanthin in krill oil. This antioxidant
might be able to exert anti-inflammatory effects and has
been found to protect against cardiovascular disease [46].
It is interesting to note that administration of antioxi-
dants such as anthocyanins and edaravone has been
shown to have beneficial effects on RA [47,48].
Figure 4 Effect of krill oil and fish oil on serum cytokine levels. 
Level of IL-1α (A), IL-1β (B) and IL-13 (C) detected in the serum from CIA 
mice on termination of the study. Data represents mean values ± SEM 
(n = 6-11). * Significantly different from control group (P < 0.05).
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Page 10 of 11Conclusions
In conclusion, krill oil provides protection in terms of
arthritis scores and joint pathology in the CIA model.
Thus, this source of (n-3) fatty acids deserves more inves-
tigation as a food supplement for patients suffering from
not only RA but also osteoarthritis and other inflamma-
tory conditions.
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